Related Experiment Video
Updated: May 11, 2026
Viral Tracing of Genetically Defined Neural Circuitry
Published on: October 17, 2012
A Method for the Production of Recombinant VSVs with Confirmation of Biological Activity
V D Moroz1, N B Gasanov1, A D Egorov1
1Sirius University of Science and Technology, Krasnodar Region, Sirius, 354340 Russian Federation.
Abstract:
The design of new effective cancer treatment methods is a promising and important research field in translational medicine. Oncolytic viruses can induce immunogenic cell death by activating the body's immune system to recognize tumor cells. This work presents the results for optimizing the production of recombinant vesicular stomatitis viruses (rVSVs). To ensure the assembly of viral particles, we developed the HEK293TN-T7 cell line, which stably expresses DNA-dependent RNA polymerase 7 for viral genome transcription, and obtained helper plasmids encoding viral genes under the control of the CAG promoter. The oncolytic activity of the purified virus preparation was assessed in a murine model of B16F10Red melanoma cells expressing a red fluorescent protein. The presented method makes it possible to obtain purified viral preparations with a high titer and oncolytic activity. The amplification of viral particles in a HEK293 suspension culture allows for rapid scalability. Therefore, the developed approach can be used to obtain other recombinant VSV-based oncolytic viruses for tumor immunotherapy.
Insights
Researchers optimized the production of recombinant vesicular stomatitis viruses (rVSVs) for cancer treatment. This scalable method yields high-titer oncolytic viruses, enhancing tumor immunotherapy potential.
Area of Science:
- Translational medicine
- Oncolytic virotherapy
- Cancer immunotherapy
Background:
- Developing effective cancer treatments is crucial.
- Oncolytic viruses offer a promising approach by triggering immune responses against tumors.
- Recombinant vesicular stomatitis viruses (rVSVs) are a focus for oncolytic virotherapy.
Purpose of the Study:
- To optimize the production of recombinant vesicular stomatitis viruses (rVSVs).
- To develop a scalable method for generating high-titer oncolytic viral preparations.
- To evaluate the oncolytic activity of the produced rVSVs.
Main Methods:
- Developed a HEK293TN-T7 cell line for stable expression of viral RNA polymerase.
- Utilized helper plasmids with CAG promoter for viral gene expression.
- Assessed oncolytic activity in a murine B16F10Red melanoma model.
Main Results:
- Successfully produced purified rVSV preparations with high titer and significant oncolytic activity.
- Demonstrated the scalability of viral particle amplification in HEK293 suspension culture.
- Validated the efficacy of the developed method for producing oncolytic viruses.
Conclusions:
- The optimized production method yields potent and scalable oncolytic rVSVs.
- This approach facilitates the development of other rVSV-based oncolytic viruses for cancer immunotherapy.
- The study contributes to advancing tumor immunotherapy strategies.
